Vivet Therapeutics - innovative gene therapy treatments for orphan diseases

innovative gene therapy treatments for orphan diseases

About us
Pipeline
Investors
News
Events
Patients & Families
Work at Vivet

Author Archives: admin_viv3t

Vivet Therapeutics → Articles by: admin_viv3t

01

Apr

Date 1 April 2017

Categories News

Vivet Therapeutics raises €37.5 million in Series A financing round

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

Author admin_viv3t

Previous page 1 … 6 7 8

Last news

Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress23 October 2023
Vivet Therapeutics awarded with the Prix Galien MedStartup in New York28 October 2021
GATEWAY clinical trial for Wilson Disease has now its website7 September 2021
VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease12 August 2021
Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease8 July 2021

Last events

AASLD – The Liver Meeting in Boston6 November 2023
ESGCT’s 30th Annual Congress in Brussels24 October 2023
Wilson Disease Association’s Annual Conference20 October 2023
Vivet presenting during the 6th annual Gene Therapy for Rare Disorders in Boston20 March 2023
Vivet presenting at the EPA World Congress in Amsterdam20 March 2023
Vivet attending World Orphan Drug Congress 2022 in Sitjes14 November 2022

About us

Our DNA
Board members
Our leadership
Partners

Pipeline

VTX-801 – Wilson’s disease
> VTX-801 in Wilson disease – GATEWAY
VTX-802 & VTX-803 – PFIC
VTX-804 – Citrullinemia Type 1

Patients & Families

Patient advocacy
Patient & Families ressources
Compassionate Use and Expanded Access

News
Events
Investors
Work at Vivet
Contact